Home » Authors » James Etheridge

Articles by James Etheridge

NicOx, Merck Sign Exclusive Antihypertensive Drug Deal

March 22, 2006

By James Etheridge

Once Profitable, Flamel Now Losing Money: $27M In 2005

March 15, 2006

By James Etheridge

Once Profitable, Flamel Now Losing Money: $27M In 2005

March 15, 2006

By James Etheridge

Cytomics Systems Secures €10M In Series B Financing

March 1, 2006

By James Etheridge

Cytomics Systems Secures €10M In Series B Financing

March 1, 2006

By James Etheridge

No Abstract

Despite Reluctance, France Drafts Bill Covering GMOs

Feb. 22, 2006

By James Etheridge

Despite Reluctance, France Drafts Bill Covering GMOs

Feb. 22, 2006

By James Etheridge

MAT BioPharma, Pierre Fabre Enter Antibody Collaboration

Feb. 15, 2006

By James Etheridge

Hybrigenics Gains Rights To Theramex’s Inecalcitol

Feb. 15, 2006

By James Etheridge

Created: Public-Private Fund For Early Investing In France

Feb. 15, 2006

By James Etheridge

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Feb. 3, 2025.
Today's news in brief
Briefs
BioWorld MedTech briefs for Jan. 30, 2026.
Centessa’s CNT-9982 shows promise for MDD
BioWorld Science
Orexin OX2 receptor agonists have demonstrated the ability to enhance wakefulness in rodent models, as well as in nonhuman primates and patients with narcolepsy...
First-in-class ADC targeting DEM-TXX shows high preclinical efficacy
BioWorld Science
Researchers at DEM Biopharma Inc. reported preclinical findings demonstrating the efficacy of DEM-301, a bifunctional antibody-drug conjugate (ADC) engineered to...
5-HT2R allosteric ligands attenuate cocaine use and seeking behavior
BioWorld Science
Serotonergic G-protein-coupled receptors (GPCRs), including the 5-HT2A receptor (5-HT2AR) and 5-HT2CR, are key regulators of cortical signaling pathways and...